Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Nasal Expiratory Resistance in Patients With Sleep Apnea and Expiratory Flow Limitation

NCT: NCT02612038 · WITHDRAWN

NCT IDNCT02612038
StatusWITHDRAWN
Start Date2016-05-01
Completion2017-05-01
SponsorBrigham and Women's Hospital (OTHER)
First posted
Last updated

Brief Summary

Obstructive sleep apnea (OSA) is inherently site-specific. In a physiological controlled intervention study, the investigators seek to determine whether applying expiratory resistance can acutely improve ventilation and sleep in patients with expiratory flow limitation (EFL).

Frequently Asked Questions

What is Nasal Expiratory Resistance in Patients With Sleep Apnea and Expiratory Flow Limitation?

Nasal Expiratory Resistance in Patients With Sleep Apnea and Expiratory Flow Limitation is a clinical trial registered under NCT02612038. Current status: WITHDRAWN.

What is the status of NCT02612038?

The current status of NCT02612038 (Nasal Expiratory Resistance in Patients With Sleep Apnea and Expiratory Flow Limitation) is: WITHDRAWN.

When did Nasal Expiratory Resistance in Patients With Sleep Apnea and Expiratory Flow Limitation start?

Nasal Expiratory Resistance in Patients With Sleep Apnea and Expiratory Flow Limitation started on 2016-05-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑